Wed October 26th, 2016
New Analysis about Nuclear Medicine/Radio-Pharmaceuticals Industry | Growing at a CAGR of 9.3% during the forecast period.
Get More Detail | Download FREE PDF Brochure@ http://tinyurl.com/zp9zgod The Nuclear Medicine/Radiopharmaceuticals market is projected to reach USD 7.27 Billion by 2021 from USD 4.67 Billion in 2016, growing at a CAGR of 9.3% during the forecast period. Growth of the overall nuclear medicine market can be attributed to factors such as the increasing number of chronic diseases like cancer, development of alpha radiotherapy, and investments through public-private partnerships. One of the popular forms of medical speciality, nuclear medicines involves application of radioactive substances in treatment of various diseases and disorders. Also known as radiopharmaceuticals, these drugs contain radio-emitting ionizing radiation, which helps them diagnose diseases and provide suitable treatment. Accurate understanding about the diseases and effective treatment are the two major advantages of nuclear medicines, which make them one of the breakthrough drugs in recent times. Rising demand and evolving technology in the healthcare industry are the strongest driving factors for the global nuclear medicine market, which is aiming at steady growth in terms of revenue and global adoption. Some of the major players in the global nuclear medicine market include Cardinal Health Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.K.), Lantheus Medical Imaging, Inc. (U.S.), Bayer AG (Germany), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), and IBA Molecular Imaging (Belgium). Stakeholders of the Nuclear Medicine Market- Radiopharmaceutical/Radioisotope Manufacturers and Distributors Healthcare Institutions (Hospitals, Medical Schools, and Outpatient Clinics) Research and Consulting Firms Research Institutes Venture Capitalists Contract Manufacturing Organizations (CMOs) Contract Research Organizations (CROs)